Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5–29; PMID:25559415; http://dx.doi.org/10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Midthun DE. Early diagnosis of lung cancer. F1000 Prime Rep 2013; 5:12; PMID:23585930; http://dx.doi.org/10.12703/P5-12
   PubMedGoogle Scholar
• Arkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, Forman D. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer 2010; 127:2918–27; PMID:21351270; http://dx.doi.org/10.1002/ijc.25517
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging C et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706–14; PMID:17762336; http://dx.doi.org/10.1097/JTO.0b013e31812f3c1a
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z et al. SEER cancer statistics review, 1975–2012. National Cancer Institute Bethesda, MD http://seercancergov/csr/1975_2012/2015
   Google Scholar
• Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354:99–105; PMID:10408484; http://dx.doi.org/10.1016/S0140-6736(99)06093-6
   PubMed Web of Science ®Google Scholar
• National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395–409; PMID:21714641; http://dx.doi.org/10.1056/NEJMoa1102873
   PubMed Web of Science ®Google Scholar
• Salvati F, Antilli A, Cruciani AR, Pau F, Flore F, Munno R, De Angelis G, Cipri A, Pigorini F. Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stage. Cancer Detect Prev 1985; 8:111–4; PMID:4064030
   PubMedGoogle Scholar
• Huang HL, Wu YC, Su LJ, Huang YJ, Charoenkwan P, Chen WL, Lee HC, Chu WC, Ho SY. Discovery of prognostic biomarkers for predicting lung cancer metastasis using microarray and survival data. BMC Bioinformatics 2015; 16:54; PMID:25881029; http://dx.doi.org/10.1186/s12859-015-0463-x
   PubMed Web of Science ®Google Scholar
• Hiura K, Shiraishi A, Suzuki C, Takamura K, Yamamoto M, Komori H, Watanabe Y, Iwaki-Egawa S. MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer. Cancer Biomark 2015; 15:433–40; PMID:25835177; http://dx.doi.org/10.3233/CBM-150483
   PubMed Web of Science ®Google Scholar
• Wang RJ, Zheng YH, Wang P, Zhang JZ. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol 2015; 8:765–71; PMID:25755772
   PubMed Web of Science ®Google Scholar
• Thunnissen E, van der Oord K, den Bakker M. Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 2014; 464:347–58; PMID:24420742; http://dx.doi.org/10.1007/s00428-014-1535-4
   PubMed Web of Science ®Google Scholar
• Ahn J, Cho J. Current serum lung cancer biomarkers. J Mol Biomark Diagn 2013; 4:2; http://dx.doi.org/10.4172/2155-9929.S4-001
   Google Scholar
• Tan EM, Zhang JY. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008; 222:328–40; PMID:18364012; http://dx.doi.org/10.1111/j.1600-065X.2008.00611.x
   PubMed Web of Science ®Google Scholar
• Zhang JY, Tan EM. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn 2010; 10:321–8; PMID:20370589; http://dx.doi.org/10.1586/erm.10.12
   PubMed Web of Science ®Google Scholar
• Liu M, Zheng SJ, Chen Y, Li N, Ren PF, Dai LP, Duan ZP, Zhang JY. Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma. J Immunol Res 2014; 2014:906532; PMID:24955377; http://dx.doi.org/10.1155/2014/906532
   PubMedGoogle Scholar
• Chai Y, Peng B, Dai L, Qian W, Zhang Y, Zhang JY. Autoantibodies response to MDM2 and p53 in the immunodiagnosis of esophageal squamous cell carcinoma. Scand J Immunol 2014; 80:362–8; PMID:24965442; http://dx.doi.org/10.1111/sji.12202
   PubMed Web of Science ®Google Scholar
• Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Jr, Hofmainster C, Alder H et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18:367–81; PMID:20951946; http://dx.doi.org/10.1016/j.ccr.2010.09.005
   PubMed Web of Science ®Google Scholar
• Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R. The MDM2-p53 pathway revisited. J Biomed Res 2013; 27:254–71; PMID:23885265; http://dx.doi.org/10.7555/JBR.27.20130030
   PubMedGoogle Scholar
• Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010; 20:299–309; PMID:20172729; http://dx.doi.org/10.1016/j.tcb.2010.01.009
   PubMed Web of Science ®Google Scholar
• Peng Q, Lao X, Chen Z, Lai H, Deng Y, Wang J, Mo C, Sui J, Wu J, Zhai L et al. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One 2013; 8:e82773; PMID:24376578; http://dx.doi.org/10.1371/journal.pone.0082773
   PubMedGoogle Scholar
• Park HS, Park JM, Park S, Cho J, Kim SI, Park BW. Subcellular localization of Mdm2 expression and prognosis of breast cancer. Int J Clin Oncol 2014; 19:842–51; PMID:24292333; http://dx.doi.org/10.1007/s10147-013-0639-1
   PubMed Web of Science ®Google Scholar
• Gunther T, Schneider-Stock R, Hackel C, Kasper HU, Pross M, Hackelsberger A, Lippert H, Roessner A. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol 2000; 13:621–6; PMID:10874665; http://dx.doi.org/10.1038/modpathol.3880107
   PubMed Web of Science ®Google Scholar
• Martin JW, Chilton-MacNeill S, Koti M, van Wijnen AJ, Squire JA, Zielenska M. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLoS One 2014; 9:e95843; PMID:24835790; http://dx.doi.org/10.1371/journal.pone.0095843
   PubMed Web of Science ®Google Scholar
• Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994; 86:1325–30; PMID:8064890; http://dx.doi.org/10.1093/jnci/86.17.1325
   PubMed Web of Science ®Google Scholar
• Grieb BC, Gramling MW, Arrate MP, Chen X, Beauparlant SL, Haines DS, Xiao H, Eischen CM. Oncogenic protein MTBP interacts with MYC to promote tumorigenesis. Cancer Res 2014; 74:3591–602; PMID:24786788; http://dx.doi.org/10.1158/0008-5472.CAN-13-2149
   PubMed Web of Science ®Google Scholar
• Volm M, Koomagi R. Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. Oncol Rep 2000; 7:95–8; PMID:10601599; http://dx.doi.org/10.3892/or.7.1.95
   PubMed Web of Science ®Google Scholar
• Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8:976–90; PMID:19029958; http://dx.doi.org/10.1038/nrc2231
   PubMed Web of Science ®Google Scholar
• van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, Van der Burg M, Green J, Vergote I. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol 1997; 50:801; PMID:9462258; http://dx.doi.org/10.1136/jcp.50.10.801
   PubMed Web of Science ®Google Scholar
• Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y, Chan EKL. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 2007; 46:107–14; PMID:17067715; http://dx.doi.org/10.1016/j.jhep.2006.08.010
   PubMed Web of Science ®Google Scholar
• Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003; 12:136–43; PMID:12582023
   PubMed Web of Science ®Google Scholar
• Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens. J Immunol Res 2014; 2014:827827; PMID:24860838; http://dx.doi.org/10.1155/2014/827827
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359–E86; PMID:25220842; http://dx.doi.org/10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006; 107:2842–9; PMID:17103443; http://dx.doi.org/10.1002/cncr.22330
   PubMed Web of Science ®Google Scholar
• Wang WJ, Tao Z, Gu W, Sun LH. Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination. Asian Pac J Cancer Prev 2013; 14:4369–71; PMID:23992005; http://dx.doi.org/10.7314/APJCP.2013.14.7.4369
   PubMedGoogle Scholar
• Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13:83–96; PMID:23303139; http://dx.doi.org/10.1038/nrc3430
   PubMed Web of Science ®Google Scholar
• Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31:1039–49; PMID:23401433; http://dx.doi.org/10.1200/JCO.2012.45.3753
   PubMed Web of Science ®Google Scholar
• Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metab Clin Exp 2015; 64:s16-21; PMID:25468140; http://dx.doi.org/10.1016/j.metabol.2014.10.027
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yu H, Hu W. The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (Shanghai) 2014; 46:180–9; PMID:24389645; http://dx.doi.org/10.1093/abbs/gmt147
   PubMed Web of Science ®Google Scholar
• Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13:49–58; PMID:12507556; http://dx.doi.org/10.1016/S1044-579X(02)00099-8
   PubMed Web of Science ®Google Scholar
• Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R. Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem 2014; 21:553–74; PMID:24180275; http://dx.doi.org/10.2174/09298673113206660325
   PubMed Web of Science ®Google Scholar
• Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14:5318–24; PMID:18765522; http://dx.doi.org/10.1158/1078-0432.CCR-07-5136
   PubMed Web of Science ®Google Scholar
• Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007; 39:1476–82; PMID:17499002; http://dx.doi.org/10.1016/j.biocel.2007.03.022
   PubMed Web of Science ®Google Scholar
• Chan S, Sikora K. The potential of oncogene products as tumour markers. Cancer Surv 1987; 6:185–207; PMID:3322544
   PubMedGoogle Scholar
• Zhang H, Gu L, Liu T, Chiang KY, Zhou M. Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. PLoS One 2014; 9:e100960; PMID:24968304; http://dx.doi.org/10.1371/journal.pone.0100960
   PubMed Web of Science ®Google Scholar
• Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004; 2:1–8; PMID:14757840
   PubMed Web of Science ®Google Scholar
• Chen X, Qiu J, Yang D, Lu J, Yan C, Zha X, Yin Y. MDM2 promotes invasion and metastasis in invasive ductal breast carcinoma by inducing matrix metalloproteinase-9. PLoS One 2013; 8:e78794; PMID:24236052; http://dx.doi.org/10.1371/journal.pone.0078794
   PubMedGoogle Scholar
• Lee KB, Ye S, Park MH, Park BH, Lee JS, Kim SM. p63-Mediated activation of the β-catenin/c-Myc signaling pathway stimulates esophageal squamous carcinoma cell invasion and metastasis. Cancer Lett 2014; 353:124–32; PMID:25045846; http://dx.doi.org/10.1016/j.canlet.2014.07.016
   PubMed Web of Science ®Google Scholar
• Boyd MT, Vlatkovic N, Haines DS. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J Biol Chem 2000; 275:31883–90; PMID:10906133; http://dx.doi.org/10.1074/jbc.M004252200
   PubMed Web of Science ®Google Scholar
• Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012; 209:679–96; PMID:22430491; http://dx.doi.org/10.1084/jem.20111512
   PubMed Web of Science ®Google Scholar